Evidence map›Paper›PMID 41573202›Full record

ReviewFrontiers in endocrinology2025

An overview of hypopituitarism's causes.

Yinbei Zhang, Zhiyue Chen, Lin Sun, Weiying Guo

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yinbei ZhangDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China.
Zhiyue ChenDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China.
Lin SunDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China.
Weiying GuoDepartment of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widespread application of tumor therapies such as immune checkpoint inhibitors and the emergence of new infectious diseases such as COVID-19 are promoting the continued expansion of the cause spectrum of hypopituitarism, making its scope significantly beyond traditional causes such as pituitary tumors and craniocerebral trauma. Faced with this evolution, a comprehensive and in-depth understanding of its etiology has become a top priority, which has also put forward new requirements for clinical diagnosis and differential diagnosis. This review aims to systematically sort out and deeply explore the etiology and pathogenesis of this disease. The content not only covers traditional factors such as pituitary tumors, radiation injury, and pituitary surgery, but also the latest progress in emerging fields such as immunotherapy, new infections, and autoimmunity. It aims to provide reliable reference for clinicians' diagnosis and treatment practice and lay a theoretical foundation for future research in this field.

Indexed as

HypopituitarismAdenomaCOVID-19HumansImmunotherapyPituitary Neoplasmsendocrinologyhypopituitarismpituitary adenomaSheehan syndrometuberculosis

Identifiers

PMID41573202
PMCPMC12819307

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.